Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Biomarker; Pharmacodynamics
- 17 Nov 2017 New trial record